EUCTR2007-001315-31-DE进行中（未招募）不适用
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients aged >= 18 years,
- •- Histologically established diagnosis of collagenous colitis (CC) defined as:
- •a) Thickened sub-epithelial collagen layer >= 10 µm on well-orientated sections
- •b) Increased amount of inflammatory cells indicating chronic inflammation in the
- •lamina propria
- •- History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in
- •patients with nexly diagnosed collagenous colitis, or history of clinical relapse for
- •more than 1 week prior screening in patients with previously established
- •collagenous colitis
- •- A mean of >= 3 stools/day, thereof a mean of >= 1 watery stolls/day, during the
- •week prior baseline
- •(not applicable for patients having participated in study BUC-60/COC and having
- •been open-labelled treated with 9 mg budesonide OD for 4 weeks under the
- •protocol BUC-60/COC in case of non-response during double-blind treatment or for
- •a relapse during the follow-up period, who are allowed to enter the open-label
- •phase of BUC-63/COC at the -4-week visit and continue with the open-label
- •instruction regimen for period week 5-8.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Other significant abnormalities at colonoscopy that may have been the cause
- •of diarrhoea, with the exception of colonic diverticulosis and polyps < 2 cm
- •- Infectious cause of diarrhoea
- •- Untreated active celiac disease
- •- Clinical suspicion of drug-induced collagenous colitis
- •- Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder
- •- Abnormal hepatic function (ALT or ALP > 2.5 x upper limit of normal ULN), liver
- •cirrhosis, or portal hypertension
- •- Local intestinal infection
- •- Radiation therapy towards the abdominal or pelvic region
- •- Diabetes mellitus, infection, glaucoma, tuberculosis, peptic uler disease, or hyper-
- •tension if careful medical monitoring is not ensured
- •- Known established cataract
- •- Established osteoporosis with T-score < -2.5
- •- Pregnancy or lactation
- •- History of cancer in the past five years
- •- History of significant bowel resection
- •- Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or
- •methotrexate) in the last 3 months
- •- Treatment with oral, rectal, or intravenous corticosteroids incl. budesonide in the
研究者
相似试验
进行中（未招募）
1 期
Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])MedDRA version: 20.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000022953EUCTR2017-002106-13-SEAthera Biotechnologies AB40
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules plus placebo in the treatment of primary biliary cirrhosis - Ursodeoxycholic acid plus budesonide vs. ursodeoxycholic acid alone in PBCPatients with Primary Biliary Cirrhosis at risk of disease progressionMedDRA version: 9.1Level: LLTClassification code 10036680Term: Primary biliary cirrhosisEUCTR2007-004040-70-ATDr. Falk Pharma GmbH183
进行中（未招募）
不适用
Study to compare the combination of ursodeoxycholic acid andbudesonide with the combination of ursodeoxycholic acid and placebo inthe treatment of primary biliary cirrhosisPBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflammatory activity in the histological assessment of the liverMedDRA version: 18.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2007-004040-70-LTDr. Falk Pharma GmbH144
进行中（未招募）
1 期
Study to compare the combination of ursodeoxycholic acid andbudesonide with the combination of ursodeoxycholic acid and placebo inthe treatment of primary biliary cirrhosisPBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflammatory activity in the histological assessment of the liverMedDRA version: 17.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2007-004040-70-SEDr. Falk Pharma GmbH144
进行中（未招募）
不适用
Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.EUCTR2006-000720-13-CZDr. Falk Pharma GmbH400